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Context: Low bone mineral density (BMD) has been associated with increased all-cause mortality.
Cause-specific mortality studies have been controversial.
Objective: The aim of the study was to investigate associations between BMD and all-cause mor-
tality and in-depth cause-specific mortality.
Design and Setting:We studied two cohorts from the prospective Rotterdam Study (RS), initiated
in 1990 (RS-I) and 2000 (RS-II) with average follow-up of 17.1 (RS-I) and 10.2 (RS-II) years until
January 2011. Baseline femoral neck BMD was analyzed in SD values. Deaths were classified ac-
cording to International Classification of Diseases into seven groups: cardiovascular diseases, can-
cer, infections, external, dementia, chronic lung diseases, and other causes. Gender-stratified Cox
and competing-risks models were adjusted for age, body mass index, and smoking.
Participants: The study included 5779 subjects from RS-I and 2055 from RS-II.
Main Outcome Measurements: We measured all-cause and cause-specific mortality.
Results:A significant inverse association between BMDand all-causemortality was found inmales
[expressed as hazard ratio (95% confidence interval)]: RS-I, 1.07 (1.01–1.13), P  .020; RS-II, 1.31
(1.12–1.55), P  .001); but it was not found in females: RS-I, 1.05 (0.99–1.11), P  .098; RS-II, 0.91
(0.74–1.12),P .362.An inverse associationwith chronic lungdiseasemortalitywas found inmales
[RS-I, 1.75 (1.34–2.29), P  .001; RS-II, 2.15 (1.05–4.42), P  .037] and in RS-I in females [1.72
(1.16–2.57); P  .008], persisting after multiple adjustments and excluding prevalent chronic ob-
structive pulmonary disease. A positive association between BMD and cancer mortality was de-
tected in females in RS-I [0.89 (0.80–0.99); P .043]. No associationwas foundwith cardiovascular
mortality.
Conclusions: BMD is inversely associated with mortality. The strong association of BMD with
chronic lung disease mortality is a novel finding that needs further analysis to clarify underlying
mechanisms. (J Clin Endocrinol Metab 99: 1834–1842, 2014)
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Osteoporosis is a condition characterized by low bonemineral density (BMD) and microarchitectural de-
terioration leading to decreased bone strength, which pre-
disposes to fragility fractures and is associated with high
morbidity andmortality (1). LowBMDhas been linked to
an increased risk of fracture-independent mortality and
could be considered a predictor of survival (2, 3). Regarding
cause-specific mortality, studies on the association between
BMD and cardiovascular disease (CVD) mortality have not
been consistent, with some showing an inverse relationwith
BMD (2, 4, 5), whereas others found no association (6, 7).
Potential gender differences have been found for both CVD
mortality and cancer-related mortality, but results remain
inconclusive (5, 8, 9). An inverse association between the
groupofremainingunspecifiedcausesofmortalityandBMD
has been found in both genders (2, 6).
Besides the association between low BMD and mortal-
ity, recent studies suggest that osteoporosis treatment re-
duces mortality, which could not be completely explained
by a decrease in fracture-relatedmortality (10). Previously
(3), we examined the relationship of femoral neck BMD
with overall mortality in the first cohort of the Rotterdam
Study (RS-I) and found an inverse association for all-cause
mortality in men but not women after an average fol-
low-up of 5.4 years. The aim of this study was to analyze
the relationship between BMD and all-cause and detailed
cause-specific mortality in males and females from two
cohorts of theRotterdamStudywith long-term follow-up.
Subjects and Methods
Study population
The Rotterdam Study is a prospective cohort study of males
and females designed to investigate the incidence and determi-
nants of chronic disabling diseases. Rationale and design have
been described previously (11). Inhabitants of the well-defined
Ommoord district in the city of Rotterdam in The Netherlands
were invited to participate; their names and addresses were
drawn from the municipal register. The RS-I, initiated in 1990,
consisted of 7983 subjects; the second cohort (RS-II), initiated in
2000, included 3011 subjects. All participants were 55 years
old at recruitment and reside in Ommoord, a district in Rotter-
dam. Analyses were performed in 5779 and 2055 subjects from
RS-I and RS-II, respectively—all with available BMDmeasured
at baseline and signed informed consent. The Rotterdam Study
was approved by theMedical EthicsCommittee of ErasmusMC.
Dual-energy x-ray absorptiometry (DXA) scanning
BMD was assessed using DXA. Trained radiographic tech-
nicians performed BMD measurements for participants with a
GE Lunar DPX-L densitometer (GE Lunar Corp), as previously
described (12). Femoral neck BMDwas chosen because it is not
affected by degenerative changes seen with age as lumbar spine
is, and it has been proposed for defining osteoporosis in epide-
miological studies (12, 13).
Covariates
Several baseline covariates known to influence both BMD
and mortality were included in the regression models, particu-
larly age, gender, body mass index (BMI), and smoking status
(14). BMI was calculated in kilograms per meter squared, from
height and weight measured in a standing position without
shoes. Smoking status was assessed by interview and coded as
never, former, and current smokers. Other potential confound-
ers were considered in additional analyses, such as physical ac-
tivity, prevalent morbidity, medication, high-sensitivity C-reac-
tive protein (hsCRP), and fracture incidence. For RS-I, a lower
limbdisability scorewas recordedusing amodified versionof the
Stanford Health Assessment Questionnaire (15). For RS-II, a
questionnaire onphysical activitywas collected. Baseline comor-
bidities were also assessed, such as prevalent myocardial infarc-
tion, dementia, type 2 diabetes mellitus, and chronic obstructive
pulmonary disease (COPD); likewise, baseline medication use
information was collected, such as bisphosphonate, hormone
replacement therapy, and systemic corticosteroid use. Myocar-
dial infarction prevalence was verified by a cardiologist, a gen-
eral practitioner (GP), or electrocardiogram. Prevalent COPD,
diabetes mellitus, and dementia were defined as previously de-
scribed (11, 16). hsCRP was assessed as a marker of inflamma-
tion. Continuous covariates are described as mean and SD if
there is normality of distribution; otherwise, median and inter-
quartile range are shown. Fracture events were obtained from
computerized records of GPs in the research area (covering 80%
of the cohort); additionally, research physicians regularly fol-
lowed participant information in GPs’ records outside the re-
search area. All reported events were verified by two trained
research physicians, who independently reviewed and coded the
information. Finally, all codedeventswere reviewedbyamedical
expert for final classification according to the InternationalClas-
sification of Diseases, 10th revision (ICD-10) (17). Participants
were followed from the baseline visit until January 1, 2007, or
until a first fracture or death occurred. In addition, thoracolum-
bar spine radiographs were collected at both the baseline visit
and the second follow-up visit (between 1997 and 1999). All
thoracolumbar spine radiographs of the follow-up visit were
scored morphometrically for the presence of vertebral fractures
using the McCloskey-Kanis method (18). If a vertebral fracture
was diagnosed, the baseline radiograph was also evaluated, and
if present, it was considered a prevalent vertebral fracture. If it
was not present at baseline, the fracture was considered as inci-
dent. Information on spinal radiographs was available for 3145
subjects with baseline DXA information.
Assessment of cause-specific mortality
Information on vital status is obtained continuously from the
municipal authorities in Rotterdam. The cohorts are monitored
formajor disease outcomes andmortality through computerized
linkage of the study database to GPs’ medical files. For subjects
who moved outside Ommoord, these data are obtained from
GPs, who report all important events through a computerized
system (3). Two research physicians independently coded the
mortality events according to ICD-10 (19).Medical specialists in
the respective field reviewed the coded events and confirmed the
diagnosis. Information on cause-specificmortalitywas available
until January, 2011.
Different causes of mortality were recorded according to
ICD-10 codes and first grouped into CVDs, cancer, and “other
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causes” (5, 6). To perform comprehensive analyses, the group of
othercauseswas furthercategorized intoexternal causes,dementia,
infections, chronic lung disease, and other causes, following a
slightlymodifiedpreviousapproach(8).Thiscategorizationyielded
seven groups:CVDs (cardio- and cerebrovascular diseases; ICD-10
codes I05-I30.0, I31, I32, I32.8, I34-I37, I42-I79, I81-I99,G95.1,
F01), cancer (codes C00-D09.9), chronic lung diseases (COPD
comprised80%of this group; codes J21.9, J39.9, J40, J42-J84.9,
J90-J96), dementia (mostly Alzheimer’s disease; codes F00, F02,
F03, F05.1), external causes (mainly fatal fractures; mostly hip
fractures, but also accidents and suicides; codes S00-T98 except
T82.7), infectiousdiseases (pneumoniaand septic shockwere the
most common; codes A00-B99, G00-G09, I30.1, I32.0, I32.1,
I33.0, J15-J18, J85–86, J41, K35-K38, K57.0, K75.0, I38-I41,
I80,M00.9,M86,N71,T82.7), andother causes (heterogeneous
group composed mainly of unspecified, unattended and sudden
death and a minority of nontumoral gastrointestinal, renal, he-
matological, and cerebral diseases, senility, and cachexia; codes
D10-D48.9, E00-E90, D50-D89.9, G10-G26, K22-K34, K40-
K52, K55.0, K56, K64, K73, K80, K83, K92, L12, L88, M05,
M06, M31, M35, N03, N04, N10,N17, N18, N28, R54, R64,
R96, R98, R99).
Statistical analyses
For analysis of all-cause and cause-specific mortality, BMD
was expressed in SD values, calculated as: (patient BMD  co-
hort BMDmean)/cohort BMD SD, specific for gender. For RS-I,
BMD was further categorized according to the number of SD
(T-scores)- below the mean BMD for young adults (age, 20–29
y), leading to three strata: osteoporosis (T-score  2.5), os-
teopenia (2.5T-score1.0), andnormal BMD(T-score
1.0). Reference values for normal BMD were extracted from
the Third National Health and Nutrition Examination Survey
(NHANES III) for a non-Hispanic white population (20). To
assess the relation between BMD and mortality, Cox propor-
tional hazard regressions were used, adjusting for age, BMI, and
smoking. The proportional hazard assumption of the Coxmod-
els was assessed using the Schoenfeld residuals-based test—the
standard diagnostic test. Both the P value for the BMD covariate
itself and the P value for the global model were taken into ac-
count. For cause-specific mortality, additional analyses were
performed, running the competing-risk regressions based on the
method of Fine and Gray (21) and taking into account informa-
tive censoring due to competing events. Proportionality was
tested, evaluating interaction terms with time. All significant
hazard ratios (HRs) reported here do not violate the proportion-
ality assumption and thus are constant over follow-up time, un-
less stated otherwise. Analyses were sex-stratified because: 1)
previous reports on gender differences have been described in the
relation between BMD and mortality; and 2) Cox proportional
hazards assumption violations were found due to gender. Be-
cause of fracture-related mortality (22), analyses were further
adjusted for fracture incidence as a time-varying covariate. HRs
with 95% confidence interval (CI) are expressed: 1) per decrease
in SDofBMD;and2) per categoryof osteopenia or osteoporosis,
setting normal BMD as the reference. In a later step, analyses
were repeated after exclusion of participants with fatal events
within the first 3 years, taking into account that low BMDmight
be a marker of underlying illness.
The association between BMD and cause-specific mortality
was evaluated through cumulative incidence curves (CICs) in-
stead of Kaplan-Meier curves, which overestimate the risk prob-
ability when there are several types of possible events (21). CICs
were calculated after running competing-risk regressions.
Results from individual cohorts were meta-analyzed.
SPSS version 17 (SPSS Inc) and Stata version 12 (StataCorp)
were used for the individual analyses. Comprehensive Meta-
Analysis version 2.0 (Biostat) was used for the meta-analysis.
Results
All-cause mortality
In total, 5779RS-I and2055RS-II subjectswere followed
for amedian of 17.1 years and amean of 10.2 years, respec-
tively. During the follow-up, 3117 deaths occurred in RS-I
and295inRS-II.Baselinecharacteristics forbothcohortsare
presented in Table 1. In both cohorts, a significant and in-
verse association between BMD and overall mortality was
found in males, expressed as HR (95% confidence interval
[CI]): RS-I, 1.07 (1.01–1.13), P  .020; RS-II, 1.31 (1.12–
1.55), P  .001. In females, there was no association with
Table 1. Baseline Characteristics of the Participants of the Rotterdam Study with Femoral Neck BMD Measurement
Available
RS-I RS-II
Males Females Males Females
n 2438 3341 954 1101
Age, y 66.5 (61.3–72.7)a 67.5 (61.5–74.0)a 61.5 (8.9)b 61.4 (7.9)b
BMI, kg/m2 25.6 (23.8–27.6)a 26.2 (23.9–29.1)a 26.7 (4.2)b 26.8 (5.8)b
FN BMD, g/cm2 0.91 (0.82–1.00)a 0.82 (0.73–0.91)a 0.97 (0.13)b 0.89 (0.14)b
Never smokers, n (%) 197 (8) 1706 (51) 502 (53) 861 (78)
Former smokers, n (%) 1517 (62) 961 (29) 206 (22) 3 (0.1)
Current smokers, n (%) 711 (29) 646 (19) 243 (25) 234 (21)
Prevalent DM, n (%) 252 (10.3) 325 (9.7) 128 (13.4) 112 (10.2)
Prevalent MI, n (%) 258 (10.6) 419 (12.5) 62 (6.5) 19 (1.7)
Abbreviations: FN, femoral neck; DM, diabetes mellitus; MI, myocardial infarction.
a Median (interquartile range).
b Mean (SD).
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overall mortality in either cohort. Adjustment for incident
fractures yielded essentially the same results (data not
shown).
Cause-specific mortality
Abrief descriptionof each cause and the frequencies are
shown in Table 2. The HRs for BMD and cause-specific
mortality adjusted for age, BMI, and smoking are shown
in Table 3.
A relationship between lower BMDand higher chronic
lung disease mortality was observed in RS-I and RS-II for
males [RS-I, HR, 1.75 (95% CI, 1.34–2.29), P  .001;
RS-II, 2.15 (1.05–4.42), P .037] and in RS-I for females
[1.72 (1.16–2.57), P .008]; whereas for females in RS-
II, a similar but nonsignificant trend was observed [1.77
(0.28–11.2); P  .544] with only two deaths due to
chronic lung disease. Most cases of chronic lung disease
mortality were due to COPD (RS-I and RS-II combined,
104 of 134 cases; 77.6%), whereas the non-COPD cases
were mainly due to interstitial pulmonary disease, pneu-
monitis, and unspecified respiratory failure. When we re-
stricted the analyses to COPD mortality, the association
between BMD and COPD mortality showed similar or
even higher HRs than for chronic lung disease mortality
(data not shown). The HR magnitudes for chronic lung
disease mortality were higher for males than females in
Table 2. Description and Frequencies of Cause-Specific Mortality for Participants With BMD Available in RS-I and
RS-II, up to 2011
Cause Description RS-I RS-II
CVD Cardio- and cerebrovascular pathology 1021 (32.8) 89 (30.1)
Cancer All cancer-related deaths 829 (26.6) 110 (37.3)
Other causes Noncancerous gastrointestinal, hematological, cerebral, and renal pathology;
cachexia; senility; unattended, unspecified, and sudden death
640 (20.5) 45 (15.3)
Dementia Dementia as final cause of death 241 (7.7) 18 (6.1)
Infectious diseases All infection-related deaths 162 (5.2) 12 (4.1)
Lung diseases COPD, interstitial diseases, respiratory failure 121 (3.9) 13 (4.4)
External causes Mainly hip fractures, accidents, suicides 91 (2.9) 7 (2.4)
Missing causes Cases without ICD-10 codification 12 (0.4) 1 (0.3)
Total 3117 (100) 295 (100)
Data are expressed as number (percentage).
Table 3. All-Cause and Cause-Specific Mortality HRs for RS-I and RS-II per Decrease in SD of Femoral Neck BMD
Males Females
No. of Deaths HR (95% CI) P No. of Deaths HR (95% CI) P
All-cause
RS-I 1488 1.07 (1.01–1.13) .020 1629 1.05 (0.99–1.11) .098
RS-II 177 1.31 (1.12–1.55) .001 118 0.91 (0.74–1.12) .362
Cardiovascular
RS-I 507 0.97 (0.88–1.07) .576 514 0.99 (0.90–1.09) .865
RS-II 52 1.24 (0.91–1.67) .168 37 0.91 (0.63–1.32) .615
Cancer
RS-I 438 1.04 (0.94–1.15) .453 391 0.89 (0.80–0.99) .043
RS-II 66 1.29 (0.99–1.68) .060 44 0.91 (0.65–1.27) .598
Other causes
RS-I 266 1.18 (1.02–1.35) .021 374 1.21 (1.07–1.37) .003
RS-II 27 1.25 (0.82–1.91) .293 18 0.66 (0.41–1.07) .092
Dementia
RS-I 67 1.08 (0.82–1.42) .594 174 1.20 (0.99–1.45) .060
RS-II 09 1.83 (0.93–3.60) .081 09 0.91 (0.40–2.08) .822
Infections
RS-I 84 1.14 (0.89–1.46) .295 78 0.93 (0.72–1.20) .572
RS-II 06 0.84 (0.41–1.74) .650 06 2.51 (0.81–7.78) .111
Chronic lung disease
RS-I 81 1.75 (1.34–2.29) .001 40 1.72 (1.16–2.57) .008
RS-II 11 2.15 (1.05–4.42) .037 02 1.77 (0.28–11.2) .544
External causes
RS-I 37 1.26 (0.86–1.82) .231 54 1.87 (1.30–2.68) .001
RS-II 05 1.58 (0.59–4.23) .361 02 0.96 (0.18–5.12) .958
Adjustments were made for age, smoking, and BMI. Boldface data corresponds to hazard ratios with statistically significant P values.
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both cohorts, and this difference remained after further
adjustments for baseline medication use, such as bispho-
sphonates andhormone replacement therapyuse (datanot
shown). Furthermore, adjustments for corticosteroid use,
prevalent and incident radiographic and clinical vertebral
fractures, log C-reactive protein (CRP) and lower limb
disability score, and exclusion of COPD prevalent cases
yielded similar results (Table 4). Figure 1A shows RS-I
CICs (ie, the probability of dying of a chronic lung disease
taking into account competing risks) for participants of
median age, according to baseline BMD in SD values and
adjusted for gender,BMI, lower limbdisability, and smok-
ing. Figure 1, B–D, shows the CICs stratified by smoking
status in RS-I. Figure 1, E–H, shows correspondent CICs
for RS-II.
There was a significant relationship between BMDand
mortality due to other causes in RS-I [for males, HR, 1.18
(95% CI, 1.02–1.35), P  .021; for females, 1.21 (1.07–
1.37), P  .003]; whereas it was not significant in RS-II.
Subanalysis of this group in RS-I attributed mortality
mainly to unattended death, sudden death–cause un-
known, and unspecified cause of mortality. For females in
RS-I, therewas a significant relationship between external
causes of mortality and BMD [1.87 (1.30–2.68); P 
.001], driven mainly by hip fracture mortality and a sig-
nificant positive association between BMD and cancer
mortality [0.89 (0.80–0.99); P  .043], whereas no as-
sociations were found in men.
Therewereno significant associationsbetweenBMDand
mortality due to CVD, dementia, or infectious diseases.
Results from competing-risk regression models were
similar to Cox models (data not shown).
The HRs from combined analysis of the two cohorts
mostly reflected the results from the much larger RS-I co-
hort, both in all-cause and in cause-specificmortality anal-
ysis (data not shown).
Further adjustments for baseline comorbidity, bispho-
sphonate use, log CRP, and physical exercise did not sub-
stantially change the results in either cohort or gender
(data not shown).
Risk of all-cause and cause-specific mortality in
subjects with osteopenia and osteoporosis
compared to those with normal BMD in RS-I
When analyzing themortality in subjects with osteope-
nia and osteoporosis compared to those with normal
BMD in RS-I, similar trends were found as with BMD in
SD, except that females with osteoporosis also had in-
creased risk of death. For all-cause mortality in RS-I, the
HR for males with osteopenia was 1.26 (95% CI, 1.10–
1.43; P  .001); and the HR for males with osteoporosis
was 2.40 (1.39–4.16; P  .002), compared with those
with normal BMD (Figure 2). Females with osteoporosis
had 1.66 (1.17–2.35; P  .004) times increased risk of
death. For chronic lung disease mortality, males with os-
teopenia had 2.21 (1.34–3.62; P .002) times increased
risk, whereas for those with osteoporosis, the risk was
increased 16.6 times (5.84–47.0;P .001). Females with
osteoporosis had 5.91 (1.20–29.0; P  .029) times in-
creased risk for chronic lung diseasemortality. Figure 2, A
andB, shows theHRs forall-causemortality andmortality
due to chronic lung disease in males and females with
normal BMD, osteopenia, and osteoporosis. These anal-
yses have been adjusted for age, BMI, and smoking. Fur-
ther adjustments for incidental fractures yielded similar
results (data not shown).
Exclusion of participants with early fatal events
Analyses excluding participants who died within the
first 3 years of follow-up did not change results essentially
(data not shown).
Discussion
In these analyses in two large prospective cohorts of el-
derly subjects from the Rotterdam Study, femoral neck
BMD in SD was significantly inversely related to overall
mortality in males but not in females. This relationship
was not driven by fracture-related mortality because ad-
justment for incident fractures yielded similar results.
Table 4. Chronic Lung Disease Mortality HRs per SD Decrease in Femoral Neck BMD in RS-I
Males Females
All Cases (n  81)
Excluding Prevalent
COPD (n  55) All Cases (n  40)
Excluding Prevalent
COPD (n  32)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Model I 1.75 (1.33–2.29) .001 1.55 (1.13–2.14) .007 1.72 (1.16–2.57) .008 1.79 (1.13–2.83) .013
Model II 1.73 (1.30–2.29) .001 1.65 (1.16–2.33) .005 1.68 (1.12–2.54) .012 1.83 (1.14–2.93) .013
Abbreviation: n, number of deaths. Model I was adjusted for age, BMI, and smoking. Model II was adjusted for age, BMI, smoking, lower limb
disability, log CRP, baseline corticosteroid use, and prevalent and incident vertebral fractures. Boldface data corresponds to hazard ratios with
statistically significant P values.
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However, both males and females with osteoporosis had
increased risk of death compared to those with normal
BMD. When assessing cause-specific mortality in detail,
we found a novel and inverse relation in both genders
between BMD and mortality related to chronic lung dis-
eases (mainly COPD). In RS-I, there was a significant in-
verse relationship between BMDand other causes ofmor-
tality in both genders, which was mainly observed in
participants with unattended, unspecified, and sudden
deaths. An inverse association of BMD with external
causes ofmortality (mainly due to hip fracture) was found
in females in RS-I. No association was found between
BMD and CVD mortality, dementia-related mortality,
and death due to infectious diseases in either cohort. To
the best of our knowledge, the relation we found between
baseline BMD and chronic lung disease mortality has not
been described before. The direction of association was
consistent between genders and study cohorts andwas not
explained by prevalent COPD. Males and females with
osteoporosis in RS-I had a 17 and 6 times increased risk of
death due to chronic lung disease, respectively. It has been
known that patients with COPD are at increased risk for
low BMD and fractures (23, 24), partly related to factors
such as older age, smoking, physical inactivity, cortico-
steroid use, and low BMI (25), the latter being one of the
more important determinants of low BMD according to a
recent systematic review (26). All of these factors have
been taken into account in our analyses, and the HRs did
not change, suggesting that other, yet unknown factors
explain this relationship between BMD and COPD mor-
tality. Chronic inflammation, associated to COPD, may
induce low BMD, but additional adjustments for hsCRP
didnotmodify theassociations.Likewise, smoking, themost
recognized environmental trigger for COPD (27), produces
profound bone loss,mainly through increased osteoclast ac-
tivity (28). Smoking induces IL-17 production, which is re-
lated to the development of emphysema (29) and is a potent
inductor of inflammatory bone loss via stimulation of recep-
tor activator of nuclear factor-B ligand (30). Nevertheless,
adjusting for smoking did not modify the association, and
competing risk regression analyses showed similar associa-
tions in smokers as in nonsmokers.
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Figure 1. A, CIC for chronic lung disease mortality according to baseline BMD expressed in SD values (BMDsd), adjusted for gender, BMI, lower
limb disability and smoking, for participants of median age of RS-I cohort. B–D, CIC according to baseline smoking status: current smokers (B),
former smokers (C), and never smokers (D). The solid line represents participants with average BMD (BMDsd  0), and the dashed line represents
participants with 3 SD below average BMD (BMDsd  3). The analysis time is in years. E, CICs for chronic lung disease mortality according to
baseline BMD expressed in BMDsd, adjusted for gender, BMI, physical activity, and smoking, for participants of median age of RS-II cohort. F–H,
CIC according to baseline smoking status: current smokers (F), former smokers (G), and never smokers (H). The solid line represents participants
with average BMD (BMDsd  0), and the dashed line represents participants with 3 SD below average BMD (BMDsd  3). The analysis time is in
years.
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Although vertebral fractures could compromise lung
function and thus mortality (31, 32), we did not find this
to be an explanation for our findings because adjustment
for prevalent and incident vertebral fractures did notmod-
ify results. Alternative explanationsmay be low vitaminD
levels, which may lead to decreased BMD, as well as im-
paired lung function, or sarcopenia, and/or physical inac-
tivity. COPD patients have a high prevalence of hypovi-
taminosis D and sarcopenia (33, 34). Unfortunately,
vitamin D levels were not available at baseline, but ad-
justing for disability index, which might be expected to
associate with both low vitaminD and physical inactivity,
did not change results. It was recently reported that the
presence of anti-citrullinated protein antibodies is related
to bone loss years before the occurrence of rheumatoid
arthritis (35, 36), while also being related to the develop-
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Figure 1. Continued.
Figure 2. All-cause (A) and chronic lung disease (B) mortality HRs for participants from RS-I, according to T-score, adjusted for age, BMI, and
smoking status. *, P  .05; **, P  .001 compared to normal T-score. x, P  .05; xx, P  .001 osteoporosis compared to osteopenia.
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ment of airway abnormalities (37). This or other common
factorsmight underlie our findings. Alternatively, a causal
relationship between osteoporosis and (deaths from)
other diseases like COPD cannot be ruled out because
bone influences multiple other tissues and organs, eg,
through its endocrine and immune-modulating properties
as has been shown by multiple recent studies (38).
Future studies should investigate a potential role of vita-
minD,body composition,muscle strength, physical activity,
and potential common factors such as anti-citrullinated pro-
tein antibodies. Also, based on our findings, it would be of
public health importance to study furtherwhether treatment
of osteoporosis inpatientswithCOPDwould influence their
mortality and potential pulmonary function.
In both studies, we found that femoral neck BMD was
significantly inversely related to overall mortality inmales
but not in females. However, female subjects with osteo-
porosis also had increased risk of death. The relation be-
tween BMD and mortality in males was explained by an
associationwithmortality fromseveral causes, and similar
findings were seen in females, except in the relation with
cancermortality.We found a decreasedHR for cancermor-
tality with decreasing BMD in females, which may explain
the absence of an association with overall mortality in fe-
males. A gender difference in cancer mortality was found in
theNHANES I cohort (5), with a significantly increasedHR
for males but not females. Possible diverging associations
between BMD and cancer mortality will have to be further
investigated in well-powered studies.
We did not find a consistent association between BMD
and CVD mortality, adding to the inconsistent literature
findings of such a relationship. We found no association
between BMD and dementia-related mortality. There is
always the possibility that a low bonemass reflects a poor
pre-existing health status, which may lead to increased
mortality. We tried to account for this by excluding par-
ticipants with mortality within the first 3 years of follow-
up, but results were essentially the same.
This study has several limitations and strengths. A po-
tential selection bias may have occurred because subjects
who came to the research center at baseline for tests were
healthier; however, if present, a dilution of the observed
effects would be expected. Also, residual confounding
cannot be excluded. Another weakness is that baseline
COPD diagnosis was made based on clinical grounds and
not in all cases on spirometry data, which is the “gold
standard”method. Therefore, we cannot exclude the pos-
sibility ofmisclassificationofCOPDstatus at baseline, but
it is not likely that this explains our finding. Also, we had no
information on cumulative dose of corticosteroids in the
past, only current use at baseline. Another potential limita-
tion stems from the fact that the entire cohort is composedof
European Caucasians, limiting the generalizability of our
findings to other populations or ethnic groups.
One strength is the availability of two large prospective
and similarly well-characterized, population-based pro-
spective studies with accurate determination of causes of
death. In general, data of The Netherlands registers is rec-
ognized as reliable and consistent (39), and more than
85% of the death registries in these cohorts were coded
with high certainty level. Aswith any survival analysis, the
completenessof follow-up is important, becausewhen low
it produces biased estimates (40). For both cohorts, the
corresponding values for completeness of follow-up were
higher than 90%, reassuring us that effect estimates ob-
tained are valid.
In summary, we found an inverse relationship between
BMD and all-cause mortality in males and an increased
risk of death for male and female subjects with osteopo-
rosis compared to those with normal BMD. This relation-
ship was explained by several underlying causes, such as
chronic lung disease mortality, trauma, and other causes.
Apotential gender difference in the relationbetweenBMD
and cancer-related mortality with a positive association
between BMD and cancer-related mortality in females
may explain the absence of an inverse relation between
BMD and all-cause mortality in females. The consistent
finding in both genders in both studies of an inverse and
strong association between baseline BMD and chronic
lung disease mortality has not been reported before and
needs further study into the underlying pathophysiologi-
cal mechanisms.
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